Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Real World Experience of Alpha-1 Antitrypsin in Treatment-Refractory Acute Graft Versus Host Disease: High Durable Response Rate | Synapse
March 3, 2026
Real World Experience of Alpha-1 Antitrypsin in Treatment-Refractory Acute Graft Versus Host Disease: High Durable Response Rate
HC
Henry Hildorf Castellani
JC
Jean Guy Caputo
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
QZ
Qiuhong Zhao
Ver todo
Puntos clave
High durable response rate observed in treatment-refractory acute graft versus host disease patients.
The response rate was reported to be over 70% among treated patients, demonstrating significant clinical benefits.
Observational analysis provided insights into the effectiveness of alpha-1 antitrypsin for managing this condition.
Results suggest potential for broader applications of alpha-1 antitrypsin in similar immunological disorders.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Castellani et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76029c6e9836116a2ca44
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.368